Cargando…

PIK3CA copy-number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer

As wider insights are gained on the molecular landscape of triple-negative breast cancer (TNBC), novel targeted therapeutic strategies might become an option in this setting as well. Activating mutations of PIK3CA represent the second most common alteration in TNBC after the TP53 mutation, with a pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amato, Ottavia, Buisseret, Laurence, Gebhart, Géraldine, Plouznikoff, Nicolas, Larsimont, Denis, Awada, Ahmad, Piccart, Martine, Aftimos, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory Press 2023
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240844/ https://www.ncbi.nlm.nih.gov/pubmed/36863843 http://dx.doi.org/10.1101/mcs.a006255

Ejemplares similares

PIK3CA copy number aberration and activation of the PI3K-AKT-mTOR pathway in varied disease states of penile cancer
por: Adimonye, Anthony, et al.
Publicado: (2018)

Somatic mutation and gain of copy number of PIK3CA in human breast cancer
por: Wu, Guojun, et al.
Publicado: (2005)

GPR41 Regulates the Proliferation of BRECs via the PIK3-AKT-mTOR Pathway
por: Meng, Zitong, et al.
Publicado: (2023)

Targeting immune checkpoints in breast cancer: an update of early results
por: Solinas, Cinzia, et al.
Publicado: (2017)

PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging
por: Duggan, Michael R., et al.
Publicado: (2021)

PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway
por: Hu, Huayu, et al.
Publicado: (2021)

Adenoid cystic carcinoma of the breast – an aggressive presentation with pulmonary, kidney, and brain metastases: a case report
por: Mhamdi, Hasnae Alaoui, et al.
Publicado: (2017)

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
por: Wang, Zhiyong, et al.
Publicado: (2014)

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
por: di Blasio, Laura, et al.
Publicado: (2018)

Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway
por: Yan, Wei, et al.
Publicado: (2021)

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
por: Brandão, Mariana, et al.
Publicado: (2019)

Immunotherapy in breast cancer: an overview of current strategies and perspectives
por: Debien, Véronique, et al.
Publicado: (2023)

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2013)

Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN
por: Laes, Jean-François, et al.
Publicado: (2017)

PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA)
por: Hori, Yumiko, et al.
Publicado: (2022)

Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors
por: Loconte, Daria C., et al.
Publicado: (2015)

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2019)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Prvanović, Mirjana, et al.
Publicado: (2021)

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer
por: Migliaccio, Ilenia, et al.
Publicado: (2022)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly
por: Rios, Jonathan J., et al.
Publicado: (2013)

New generation of breast cancer clinical trials implementing molecular profiling
por: Zardavas, Dimitrios, et al.
Publicado: (2016)

PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway
por: Zhang, Wei, et al.
Publicado: (2014)

Correction: PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibro-adipose vascular anomaly (FAVA)
por: Hori, Yumiko, et al.
Publicado: (2022)

LACTB Regulates PIK3R3 to Promote Autophagy and Inhibit EMT and Proliferation Through the PI3K/AKT/mTOR Signaling Pathway in Colorectal Cancer
por: Xu, Wei, et al.
Publicado: (2020)

Aspirin promotes RSL3-induced ferroptosis by suppressing mTOR/SREBP-1/SCD1-mediated lipogenesis in PIK3CA-mutatnt colorectal cancer
por: Chen, Hao, et al.
Publicado: (2022)

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
por: Smith, Alison E., et al.
Publicado: (2023)

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA(+) oral cancers
por: Yamaguchi, Kosuke, et al.
Publicado: (2016)

miR‐126 reduces trastuzumab resistance by targeting PIK3R2 and regulating AKT/mTOR pathway in breast cancer cells
por: Fu, Rao, et al.
Publicado: (2020)

The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS)
por: Suzuki, Yasuyo, et al.
Publicado: (2017)

MicroRNA-363-3p inhibits cell proliferation and induces apoptosis in retinoblastoma cells via the Akt/mTOR signaling pathway by targeting PIK3CA
por: Ma, Xiaojie, et al.
Publicado: (2020)

Positive correlation between transcriptomic stemness and PI3K/AKT/mTOR signaling scores in breast cancer, and a counterintuitive relationship with PIK3CA genotype
por: Madsen, Ralitsa R., et al.
Publicado: (2021)

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis
por: Bareche, Y, et al.
Publicado: (2018)

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

pAKT pathway activation is associated with PIK3CA mutations and good prognosis in luminal breast cancer in contrast to p-mTOR pathway activation
por: Sonnenblick, Amir, et al.
Publicado: (2019)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
por: Ma, Jing, et al.
Publicado: (2023)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
por: Buisseret, Laurence, et al.
Publicado: (2023)

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
por: Cossu-Rocca, Paolo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eembapr528mkmpb3bi7u0itgql